Literature DB >> 17134371

Immunosuppressive strategies that are mediated by tumor cells.

Gabriel A Rabinovich1, Dmitry Gabrilovich, Eduardo M Sotomayor.   

Abstract

Despite major advances in understanding the mechanisms leading to tumor immunity, a number of obstacles hinder the successful translation of mechanistic insights into effective tumor immunotherapy. Such obstacles include the ability of tumors to foster a tolerant microenvironment and the activation of a plethora of immunosuppressive mechanisms, which may act in concert to counteract effective immune responses. Here we discuss different strategies employed by tumors to thwart immune responses, including tumor-induced impairment of antigen presentation, the activation of negative costimulatory signals, and the elaboration of immunosuppressive factors. In addition, we underscore the influence of regulatory cell populations that may contribute to this immunosuppressive network; these include regulatory T cells, natural killer T cells, and distinct subsets of immature and mature dendritic cells. The current wealth of preclinical information promises a future scenario in which the synchronized blockade of immunosuppressive mechanisms may be effective in combination with other conventional strategies to overcome immunological tolerance and promote tumor regression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17134371      PMCID: PMC2895922          DOI: 10.1146/annurev.immunol.25.022106.141609

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  186 in total

1.  Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo.

Authors:  Abdelilah Wakkach; Nathalie Fournier; Valérie Brun; Jean-Philippe Breittmayer; Françoise Cottrez; Hervé Groux
Journal:  Immunity       Date:  2003-05       Impact factor: 31.745

2.  Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.

Authors:  F Stephen Hodi; Martin C Mihm; Robert J Soiffer; Frank G Haluska; Marcus Butler; Michael V Seiden; Thomas Davis; Rochele Henry-Spires; Suzanne MacRae; Ann Willman; Robert Padera; Michael T Jaklitsch; Sridhar Shankar; Teresa C Chen; Alan Korman; James P Allison; Glenn Dranoff
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-07       Impact factor: 11.205

3.  Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.

Authors:  Tyler J Curiel; Shuang Wei; Haidong Dong; Xavier Alvarez; Pui Cheng; Peter Mottram; Roman Krzysiek; Keith L Knutson; Ben Daniel; Maria Carla Zimmermann; Odile David; Matthew Burow; Alan Gordon; Nina Dhurandhar; Leann Myers; Ruth Berggren; Akseli Hemminki; Ronald D Alvarez; Dominique Emilie; David T Curiel; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2003-04-21       Impact factor: 53.440

4.  Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species.

Authors:  Sergei Kusmartsev; Dmitry I Gabrilovich
Journal:  J Leukoc Biol       Date:  2003-08       Impact factor: 4.962

5.  Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas.

Authors:  William Vermi; Raffaella Bonecchi; Fabio Facchetti; Denise Bianchi; Silvano Sozzani; Silvana Festa; Angiola Berenzi; Marina Cella; Marco Colonna
Journal:  J Pathol       Date:  2003-06       Impact factor: 7.996

Review 6.  Adoptive-cell-transfer therapy for the treatment of patients with cancer.

Authors:  Mark E Dudley; Steven A Rosenberg
Journal:  Nat Rev Cancer       Date:  2003-09       Impact factor: 60.716

7.  BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1.

Authors:  Norihiko Watanabe; Maya Gavrieli; John R Sedy; Jianfei Yang; Francesca Fallarino; Susan K Loftin; Michelle A Hurchla; Natalie Zimmerman; Julia Sim; Xingxing Zang; Theresa L Murphy; John H Russell; James P Allison; Kenneth M Murphy
Journal:  Nat Immunol       Date:  2003-06-08       Impact factor: 25.606

8.  Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion.

Authors:  Andrew L Mellor; Babak Baban; Phillip Chandler; Brendan Marshall; Kanchan Jhaver; Anna Hansen; Pandelakis A Koni; Makio Iwashima; David H Munn
Journal:  J Immunol       Date:  2003-08-15       Impact factor: 5.422

9.  Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

Authors:  Willem W Overwijk; Marc R Theoret; Steven E Finkelstein; Deborah R Surman; Laurina A de Jong; Florry A Vyth-Dreese; Trees A Dellemijn; Paul A Antony; Paul J Spiess; Douglas C Palmer; David M Heimann; Christopher A Klebanoff; Zhiya Yu; Leroy N Hwang; Lionel Feigenbaum; Ada M Kruisbeek; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2003-08-18       Impact factor: 14.307

10.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.

Authors:  Giao Q Phan; James C Yang; Richard M Sherry; Patrick Hwu; Suzanne L Topalian; Douglas J Schwartzentruber; Nicholas P Restifo; Leah R Haworth; Claudia A Seipp; Linda J Freezer; Kathleen E Morton; Sharon A Mavroukakis; Paul H Duray; Seth M Steinberg; James P Allison; Thomas A Davis; Steven A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-25       Impact factor: 12.779

View more
  621 in total

1.  The role of Gr1+ cells after anti-CD20 treatment in type 1 diabetes in nonobese diabetic mice.

Authors:  Changyun Hu; Wei Du; Xiaojun Zhang; F Susan Wong; Li Wen
Journal:  J Immunol       Date:  2011-12-02       Impact factor: 5.422

2.  Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12.

Authors:  Mariana Malvicini; Mariana Ingolotti; Flavia Piccioni; Mariana Garcia; Juan Bayo; Catalina Atorrasagasti; Laura Alaniz; Jorge B Aquino; Jaime A Espinoza; Manuel Gidekel; O Graciela Scharovsky; Pablo Matar; Guillermo Mazzolini
Journal:  Mol Oncol       Date:  2011-04-05       Impact factor: 6.603

3.  Immunomodulatory glc/man-directed Dolichos lablab lectin (DLL) evokes anti-tumour response in vivo by counteracting angiogenic gene expressions.

Authors:  V Vigneshwaran; P Thirusangu; B R Vijay Avin; V Krishna; S N Pramod; B T Prabhakar
Journal:  Clin Exp Immunol       Date:  2017-04-05       Impact factor: 4.330

4.  B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma.

Authors:  Dong Hua; Jing Sun; Yong Mao; Lu-Jun Chen; Yu-Yu Wu; Xue-Guang Zhang
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

Review 5.  Dietary agents in cancer prevention: an immunological perspective.

Authors:  Ya Ying Zheng; Bharathi Viswanathan; Pravin Kesarwani; Shikhar Mehrotra
Journal:  Photochem Photobiol       Date:  2012-03-30       Impact factor: 3.421

Review 6.  Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.

Authors:  Theresa L Whiteside
Journal:  Expert Opin Biol Ther       Date:  2010-07       Impact factor: 4.388

Review 7.  Design and development of therapies using chimeric antigen receptor-expressing T cells.

Authors:  Gianpietro Dotti; Stephen Gottschalk; Barbara Savoldo; Malcolm K Brenner
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 8.  Blinatumomab for the treatment of acute lymphoblastic leukemia.

Authors:  Jason B Kaplan; Marina Grischenko; Francis J Giles
Journal:  Invest New Drugs       Date:  2015-09-17       Impact factor: 3.850

9.  Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy.

Authors:  Samuel Kim; George Buchlis; Zvi G Fridlender; Jing Sun; Veena Kapoor; Guanjun Cheng; Andrew Haas; Hung Kam Cheung; Xiamei Zhang; Michael Corbley; Larry R Kaiser; Leona Ling; Steven M Albelda
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

Review 10.  Plant-derived polysaccharides activate dendritic cell-based anti-cancer immunity.

Authors:  Siambi Kikete; Li Luo; Beitian Jia; Li Wang; Gregory Ondieki; Yuhong Bian
Journal:  Cytotechnology       Date:  2018-03-19       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.